Inclusion Criteria:

          -  Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical
             (IHC) staining for p53

          -  Disease Progression between 4 weeks - 6 months after the last platinum-based treatment
             was administered

          -  At least a single measurable lesion

          -  Adequate organ function prior to registration

          -  Toxicities from previous cancer therapies (excluding alopecia) must have recovered to
             grade 1 (defined by National Cancer Institute [NCI] Common Terminology Criteria for
             Adverse Events [CTCAE] version 4.0). Chronic stable grade 2 peripheral neuropathy
             secondary to neurotoxicity from prior therapies may be considered on a case by case
             basis

          -  ECOG performance status of 0 to 2

        Exclusion Criteria:

          -  Prior exposure to cumulative doses of doxorubicin >400 mg/m2 or epirubicin >720 mg/m2

          -  Hypersensitivity to PLD or to any of the excipients

          -  Unable to undergo imaging by either CT scan or MRI

          -  Evidence of any other medical conditions (such as psychiatric illness, infectious
             diseases, neurological conditions, physical examination or laboratory findings) that
             may interfere with the planned treatment, affect patient compliance or place the
             patient at high risk from treatment related complications

          -  Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma
             in situ)

          -  Is taking concurrent (or within 4 weeks prior to registration) chemotherapy,
             immunotherapy, radiotherapy, or any ancillary therapy that is considered to be
             investigational (i.e., used for non-approved indications(s) and in the context of a
             research investigation). Supportive care measures are allowed. Palliative limited
             radiation therapy for pain reduction is allowed